Identifying novel autoantibody signatures in ovarian cancer using high-density protein microarrays.
To identify autoantibody signatures in ovarian cancer using protein microarray technology. Protein microarrays were screened using non-malignant peritoneal fluid (n=30) and ascites fluid pooled from ovarian cancer patients (n=30). Fifteen potential tumour-associated antigens were discovered. AASDHPPT showed the strongest signal-to-noise ratio. Protein microarrays are suitable for autoantibody discovery in ovarian cancer but the signatures are of low frequency.